Director Anja B. Krammer filed a Form 4 with the SEC on October 27, 2026, disclosing the grant of 12,000 stock options in Vivos Therapeutics, Inc. on September 14, 2026.

Key Highlights

  • Grant date: Vivos Therapeutics granted 12,000 stock options to Director Anja B. Krammer on September 14, 2026.
  • Exercise price: The options carry an exercise price of $0.18 per share, according to the filing.
  • Vesting schedule: One-half vested immediately on the grant date, one-fourth vests on September 30, 2026, and one-fourth vests on December 31, 2026.
  • Expiration: The options are exercisable for a period of 10 years from the grant date, expiring September 14, 2036.
  • Post-transaction holdings: Following the reported transaction, Krammer beneficially owns 17,200 derivative securities (stock options) on a direct basis.
  • Prior option expirations: The filing notes 667 options expired unexercised on June 19, 2025, and 1,200 options expired unexercised on August 5, 2026.

Vivos Therapeutics Director Krammer Receives Stock Option Grant in September 2026

According to the Form 4 filed on October 27, 2026, Anja B. Krammer, a director of Vivos Therapeutics, Inc. (NASDAQ:VVOS), received a grant of 12,000 stock options on September 14, 2026. The options are classified as "Stock Options (Right to Buy)" common stock and were acquired under transaction code "A," indicating an award. The filing was signed by Bradford K. Amman as attorney-in-fact for Anja B. Krammer.

The filing discloses that the options were granted at an exercise price of $0.18 per share. The vesting structure, as described in the filing's explanation of responses, is as follows: one-half vested immediately on the grant date of September 14, 2026; one-fourth will vest on September 30, 2026; and the remaining one-fourth will vest on December 31, 2026. The options have a 10-year exercise period running from the grant date to September 14, 2036. The price of the derivative security at the time of grant is listed as $0 in the filing.

Following the reported transaction, the filing states that Krammer directly and beneficially owns 17,200 stock options in total. The filing also notes that 667 options previously held by Krammer expired unexercised on June 19, 2025, and a further 1,200 options expired unexercised on August 5, 2026, with both expirations reflected in the post-transaction totals disclosed. No non-derivative securities transactions were reported in Table I of this filing.

What Was Disclosed

Director Anja B. Krammer disclosed the receipt of 12,000 stock options in Vivos Therapeutics, Inc. on September 14, 2026, at an exercise price of $0.18, with a split vesting schedule and a 10-year term. Her total beneficial ownership of stock options following the transaction is reported as 17,200.